Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 21, 2020
- Accepted in final form January 21, 2021
- First Published March 29, 2021.
Author Disclosures
- Niklas Joisten, PhD*,
- Annette Rademacher*,
- Clemens Warnke, MD,
- Sebastian Proschinger,
- Alexander Schenk, PhD,
- David Walzik,
- Andre Knoop, PhD,
- Mario Thevis, PhD,
- Falk Steffen,
- Stefan Bittner, MD,
- Roman Gonzenbach, MD,
- Jan Kool, PhD,
- Wilhelm Bloch, MD,
- Jens Bansi, PhD† and
- Philipp Zimmer, PhD, PhD†
- Niklas Joisten, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Annette Rademacher*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Clemens Warnke, MD,
Biogen, Novartis, Roche, Janssen; institutional fees only.
NONE
Speakers honoraria Novartis, Biogen, Bayer, Genzyme, Alexion. Institutional fees only.
Frontiers in Neurology, associate editor, 2016-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Speakers honoraria payed to the institution: Novartis, Biogen, Roche.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sebastian Proschinger,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alexander Schenk, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Walzik,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andre Knoop, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mario Thevis, PhD,
NONE
NONE
NONE
(1) Drug Testing & Analysis, Editor-in-Chief, 11 years (2) Rapid Communications in Mass Spectrometry, Adv. Board Member, 14 years (3) Current Proteomics, Adv. Board Member, 14 years (3) GH & IGF Research, Adv. Board Member, 4 years (4) Mass Spectrometry Reviews, Adv. Board Member, 1 year (5) German Journal of Sports Medicine, Adv. Board Member, 3 years
NONE
NONE
NONE
NONE
NONE
(1) World Anti-Doping Agency (WADA), Expert Group Member
NONE
NONE
NONE
NONE
(1) Partnership for Clean Competition (PCC) (2) World Anti-Doping Agency (WADA)
NONE
NONE
NONE
NONE
NONE
NONE
- Falk Steffen,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan Bittner, MD,
NONE
NONE
S. B. has received funding for travel expenses for attending meetings from Novartis and Merck Serono and honoraria from Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Genzyme and TEVA.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) German Research Council (DFG, CRC-TR-128)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Roman Gonzenbach, MD,
(1) Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Neurorehabilitation Klinik Valens, HIIT, 5% (of all patients perform HIIT), 2016 - now
NONE
NONE
NONE
(1) Swiss MS Society (2) Stiftung Grenzen überschreiten (=foundation 'crossing boundaries') (3) Stiftung Ergotherapie
NONE
NONE
NONE
NONE
NONE
NONE
- Jan Kool, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Swiss Multiple Sclerosis Society, a non for profit patient organization, no Grant Nr. available
NONE
NONE
NONE
NONE
NONE
Merck pharma, consultancy related to fatique management in persons woith Multiple Sclerosis, 2019-2020
- Wilhelm Bloch, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jens Bansi, PhD† and
NONE
NONE
Speaker honoraria for (1) Commercial, Merck; (2) Commercial, Almirall.
Frontiers
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Swiss Multiple Sclerosis Society; (2) Swiss Occupational Society; (2) "Grenzen überschreiten" (Crossing-boundries)
NONE
NONE
NONE
NONE
NONE
NONE
- Philipp Zimmer, PhD, PhD†
NONE
NONE
NONE
Editorial Board International Journal of Sports Medicine
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of “Performance and Health (Sports Medicine)” (N.J., A.S., D.W., P.Z.), Institute of Sport and Sport Science, Technical University Dortmund; Department for Molecular and Cellular Sports Medicine (A.R., S.P., W.B.), Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne; Department of Neurology (C.W.), Faculty of Medicine and University Hospital Cologne, University of Cologne; Center for Preventive Doping Research/Institute of Biochemistry (A.K., M.T.), German Sport University Cologne; Department of Neurology (F.S., S.B.), Focus Program Translational Neuroscience (FTN), and Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University, Germany; and Department of Neurology (R.G., J.K., J.B.), Clinics of Valens, Rehabilitation Centre Valens, Switzerland.
- Correspondence
Dr. Zimmer philipp.zimmer{at}tu-dortmund.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MSThanos Tsaktanis, Tobias Beyer, Lucy Nirschl et al.Neurology: Neuroimmunology & Neuroinflammation, December 24, 2020 -
Article
Dynamic regulation of serum aryl hydrocarbon receptor agonists in MSVeit Rothhammer, Davis M. Borucki, Maria Isabel Garcia Sanchez et al.Neurology: Neuroimmunology & Neuroinflammation, June 16, 2017 -
Article
The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple SclerosisAna Cirac, Thanos Tsaktanis, Tobias Beyer et al.Neurology: Neuroimmunology & Neuroinflammation, July 23, 2021 -
Editorial
Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activityJoseph J. Sabatino, Jr, Scott S. Zamvil et al.Neurology: Neuroimmunology & Neuroinflammation, June 16, 2017